First Sales of Striate+™ in New and Significant Market of Canada
Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the key market of Canada.
September 6, 2024
The Australian | Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada
Orthocell’s entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in the article “Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada”.
September 6, 2024
Petra Capital Research Report | September 2024
Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share. The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+. The author noted: “FY24 saw OCC’s Remplir and Striate products continue […]
September 4, 2024
Orthocell submits Singapore Regulatory Application for Striate+™
Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).
July 29, 2024
Orthocell Accelerates Global Market Expansion of Striate+™ and Remplir™ With Seven New Regulatory Applications either in progress or planned
Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned for its medical device platform products.
July 24, 2024
Proactive | Interview with Paul Anderson
Following the announcement that Orthocell is accelerating its global market expansion of Striate+™ and Remplir™, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s seven regulatory applications in progress or planned, targeting approval in significant markets. Paul spoke of the positive feedback from clinicians on Orthocell’s innovative regenerative medicine products and […]
July 24, 2024
Orthocell Receives Regulatory Approval to Commence Sales of Striate+™ in Canada
Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+™, in the key market of Canada.
July 11, 2024
Proactive Interview | Record-breaking revenue for FY24
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company’s record-breaking revenue for the June 24 quarter and for FY24.
July 10, 2024
Business News | Orthocell posts record revenue
Orthocell’s record revenue for FY24 has been reported in Business News.
July 10, 2024
The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
News of Orthocell’s record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business Review.
July 10, 2024